Patents Assigned to Mount Sinai School of Medicine of New York University
-
Publication number: 20180085437Abstract: This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the compositions.Type: ApplicationFiled: August 14, 2017Publication date: March 29, 2018Applicant: Mount Sinai School of Medicine of New York UniversityInventor: Jian-Qiang FAN
-
Patent number: 9625444Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: GrantFiled: March 20, 2014Date of Patent: April 18, 2017Assignees: SANOFI PASTEUR VAXDESIGN CORPORATION, THE SCRIPPS RESEARCH INSTITUTE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: William L Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Hacohen, Bruce Torbett
-
Patent number: 9597377Abstract: This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the compositions.Type: GrantFiled: December 23, 2005Date of Patent: March 21, 2017Assignee: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventor: Jian-Qiang Fan
-
Patent number: 9062122Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.Type: GrantFiled: January 18, 2008Date of Patent: June 23, 2015Assignee: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans Joerg Fehling
-
Patent number: 8841322Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.Type: GrantFiled: April 22, 2013Date of Patent: September 23, 2014Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano
-
Publication number: 20140273209Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: ApplicationFiled: March 20, 2014Publication date: September 18, 2014Applicants: SANOFI PASTEUR VAXDESIGN CORPORATION, THE SCRIPPS RESEARCH INSTITUTE, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: William L WARREN, Heather FAHLENKAMP, Russell HIGBEE, Anatoly KACHURIN, Conan LI, Mike NGUYEN, Robert PARKHILL, Guzman SANCHEZ-SCHMITZ, Darrell J. IRVINE, Gwendalyn J. RANDOLPH, Nir HACOHEN, Bruce TORBETT
-
Publication number: 20140206718Abstract: A method of enhancing the activity of lysosomal ?-Galactosidase A (?-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.Type: ApplicationFiled: December 20, 2013Publication date: July 24, 2014Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii
-
Patent number: 8633221Abstract: A method of enhancing the activity of lysosomal ?-Galactosidase A (?-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.Type: GrantFiled: November 23, 2009Date of Patent: January 21, 2014Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii
-
Publication number: 20130178918Abstract: Disclosed herein is a novel method of treating vitiligo by using an excimer laser that emits light in the UVB range. The invention includes a method of incrementally increasing exposure of affected vitiligo areas with UVB laser light from an excimer laser to restore pigmentation to skin areas afflicted with vitiligo.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: Mount Sinai School of Medicine of New York UniversityInventor: Mount Sinai School of Medicine of New York University
-
Patent number: 8436018Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.Type: GrantFiled: September 24, 2010Date of Patent: May 7, 2013Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano
-
Patent number: 8435948Abstract: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.Type: GrantFiled: September 27, 2005Date of Patent: May 7, 2013Assignees: Mount Sinai School of Medicine of New York University, University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Mone Zaidi, Harry C. Blair
-
Publication number: 20130078230Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.Type: ApplicationFiled: November 16, 2012Publication date: March 28, 2013Applicants: Genzyme Corporation, Mount Sinai School of Medicine of New York UniversityInventors: Mount Sinai School of Medicine of New York Unive, Genzyme Corporation
-
Publication number: 20130078231Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.Type: ApplicationFiled: November 16, 2012Publication date: March 28, 2013Applicants: Genzyme Corporation, Mount Sinai School of Medicine of New York UniversityInventors: Mount Sinai School of Medicine of New York Unive, Genzyme Corporation
-
Publication number: 20130035243Abstract: Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLF6wt), in particular any one of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods for diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein.Type: ApplicationFiled: June 21, 2012Publication date: February 7, 2013Applicant: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: John Martignetti, Goutham Narla, Scott Friedman
-
Publication number: 20120295868Abstract: The invention relates to a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto for use in the treatment of asthma and related diseases of abnormal pulmonary function in an animal. Also described is a method of treating asthma and related diseases of abnormal pulmonary function in an animal comprising administering to said animal an effective amount of a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto.Type: ApplicationFiled: July 30, 2012Publication date: November 22, 2012Applicants: Mount Sinai School of Medicine of New York University, Biotec Pharmacon ASAInventors: Rolf SELJELID, Xiu-Min LI
-
Patent number: 8271414Abstract: Methods, systems and apparatus for characterizing networks are presented. For example, a method of characterizing a network represented by a plurality of nodes and a plurality of edges is provided. The method may be implemented on a processor device and includes calculating, for example, by the processor device, a passthrough count of at least a portion of the network. The passthrough count includes a count of a number of passthroughs in the at least a portion of the network. A passthrough includes one of the plurality of nodes, a directed edge of the plurality of edges coupled to the one of the plurality of nodes, and another edge of the plurality of edges coupled to the one of the plurality of nodes. At most one of the directed edge and the other edge is directed towards the one of the plurality of nodes. At most one of the directed edge and the other edge is directed away from the one of the plurality of nodes.Type: GrantFiled: July 24, 2009Date of Patent: September 18, 2012Assignees: International Business Machines Corporation, Mount Sinai School of Medicine of New York UniversityInventors: Guillermo Alberto Cecchi, Srinivas Ravi Viraraghava Iyengar, Avi Ma'ayan, Ravishankar Rao, Gustavo Alejandro Stolovitzky, John Michael Wagner
-
Publication number: 20120220492Abstract: Methods to improve the tropism or other features of a virus are disclosed. Such methods can be used to prepare, e.g., DNA or plasmid libraries of variants of a gene encoding a viral capsid or envelope protein having a randomly inserted restriction site, libraries of viral clones with such variant genes with a randomly inserted restriction site or polypeptide sequence targeting a receptor expressed by a specific type of mammalian cells. Described are also methods to prepare mosaic viruses, i.e., viral particles wherein copies of one or more capsid or envelope proteins originate from different sources. These methods can be used to prepare mosaic viruses of a specific mixture of wild-type and mutant proteins, or of different types of mutant proteins.Type: ApplicationFiled: September 28, 2011Publication date: August 30, 2012Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Thomas Weber, Laure Gigout
-
Patent number: 8246945Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: GrantFiled: October 2, 2009Date of Patent: August 21, 2012Assignees: University of Arkansas, Mount Sinai School of Medicine of New York University, Allertein Therapeutics, LLCInventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
-
Publication number: 20120142634Abstract: The disclosure provides methods for treating or preventing a cancerous condition, such as multiple myeloma, by administering a therapeutically effective combination of a proteasome inhibitor and salubrinal.Type: ApplicationFiled: November 10, 2009Publication date: June 7, 2012Applicant: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: Denis M. Schewe, Julio A. Aguirre-Ghiso
-
Publication number: 20120114613Abstract: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.Type: ApplicationFiled: July 14, 2010Publication date: May 10, 2012Applicant: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: GORDON M. KELLER, VALERIE KOUSKOFF, ATSUSHI KUBO, HANS JOERG FEHLING